Promising combo for tough blood cancer hits roadblock
NCT ID NCT04160052
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study looked at combining two drugs, venetoclax and azacitidine, to treat people with a serious type of bone marrow cancer called high-risk myelodysplastic syndrome (MDS). The goal was to find the safest dose and see if the combination could shrink or control the cancer. The trial included both new patients and those whose cancer had returned or stopped responding to treatment, but it was ended early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.